Doctors Revision

Vitamin B12: pharmacology, deficiency, replacement and clinical monitoring

Text size
On this page

Overview

Haematinics • Cobalamin

Vitamin B12 (cobalamin) is essential for DNA synthesis, myelin integrity and red-cell maturation. Deficiency causes megaloblastic anaemia, glossitis and neuropsychiatric disease — and the defining difference from folate deficiency is that B12 deficiency injures the nervous system even when the blood count is normal. Never wait for macrocytosis before considering it.

Learning objectives

  • Explain intrinsic-factor-dependent absorption.
  • Identify dietary and malabsorptive causes and risk groups.
  • Distinguish B12 from folate deficiency using clinical and laboratory clues.
  • Interpret the investigation pathway, including MMA and intrinsic-factor antibodies.
  • Choose oral versus parenteral replacement and monitor neurological recovery safely.

Absorption and pharmacology

Food B12 is released in the stomach, binds salivary haptocorrin, then — after pancreatic digestion — binds intrinsic factor (IF) from gastric parietal cells. The IF–B12 complex is absorbed in the terminal ileum, travels on transcobalamin to tissues, and is stored mainly in the liver. Body stores are large, which is why deficiency may take years to appear after absorption fails.

Two enzymes depend on B12: methionine synthase (folate recycling and homocysteine metabolism) and methylmalonyl-CoA mutase — so deficiency raises both homocysteine and methylmalonic acid (MMA).

Causes and risk groups

Scroll the table sideways on a smaller screen.

Causes and risk groups
CauseExamplesClinical implication
Autoimmune malabsorptionPernicious anaemia, autoimmune gastritisIntrinsic-factor failure; long-term replacement; review for associated autoimmune disease
Gastric causesGastrectomy, bariatric surgery, chronic atrophic gastritisReduced acid/IF handling; assess lifelong risk
Ileal / pancreatic causesCrohn disease, terminal-ileal resection, coeliac disease, bacterial overgrowth, pancreatic insufficiencyAbsorption unreliable; parenteral therapy often required
Low intakeStrict unsupplemented vegan diet, food insecurity, frailtyDietary replacement may succeed if absorption intact
Medicine-relatedMetformin, acid-suppressing therapyReview duration and alternatives; do not stop essential medicines without a clinician

Clinical presentation

  • Haematological: fatigue, pallor, exertional dyspnoea, macrocytosis, glossitis, mouth ulcers; severe cases add leukopenia and thrombocytopenia.
  • Neurological: numbness and tingling, lost vibration and position sense, gait imbalance, weakness, visual change and subacute combined degeneration of the cord.
  • Neuropsychiatric: poor concentration, memory change, depression, irritability, psychosis, cognitive decline.
  • Paediatric: poor growth, developmental delay or regression in severe deficiency.

Diagnosis

Scroll the table sideways on a smaller screen.

Diagnostic tests and interpretation
AssessmentUse
FBC and filmMacrocytosis, macro-ovalocytes, hypersegmented neutrophils; a normal MCV does not exclude deficiency if iron deficiency or thalassaemia coexist
Serum B12Initial biochemical test; interpret borderline values with symptoms, medicines and assay limitations
MMA ± homocysteineHelpful in uncertain cases; MMA is specific for B12 deficiency but rises in renal impairment
Anti-intrinsic-factor antibodiesSupport pernicious anaemia when clinically appropriate
Cause investigationDiet, alcohol, drug and surgical history; assess gastric, ileal and coeliac-disease risk

Urgent escalation: new gait disorder, rapidly progressive sensory loss, severe weakness, cognitive change, severe anaemia or pancytopenia needs urgent senior assessment and prompt replacement — not routine delayed follow-up.

Replacement principles

Oral cyanocobalamin

Appropriate for dietary deficiency and selected patients with intact absorption, using local guidelines with reliable follow-up. High oral doses can be absorbed passively even in some malabsorptive states, but that is a cause-specific decision.

IM hydroxocobalamin

Standard where deficiency is due to malabsorption, pernicious anaemia, significant symptoms or neurological involvement. A NICE-based schedule uses 1 mg IM three times weekly for two weeks without neurological involvement, then maintenance; neurological involvement requires 1 mg IM on alternate days until no further improvement, followed by maintenance. Apply the local protocol — do not copy a schedule blindly.

Maintenance

Irreversible malabsorption usually needs lifelong replacement (commonly 1 mg IM every 2–3 months after repletion); dietary deficiency may allow oral maintenance after stores are restored. Review the cause before stopping injections.

Drug summary table

Scroll the table sideways on a smaller screen.

Vitamin B12 preparations
PreparationDose (adult)IndicationAdverse effects / cautions
Hydroxocobalamin IMLoading: 1 mg IM 3×/week for 2 weeks (no neurological involvement); neurological involvement: 1 mg IM alternate days until no further improvement. Maintenance: 1 mg IM every 2–3 monthsMalabsorption, pernicious anaemia, neurological disease; drug of choice for repletionInjection-site pain; transient hypokalaemia during early haematological response (potassium shifts into new cells); rare hypersensitivity
Cyanocobalamin oral50–100 micrograms daily (dietary maintenance); 1–2 mg daily for malabsorption (high-dose oral regimens)Dietary deficiency; maintenance where absorption intact; selected high-dose oral protocols for malabsorptionGenerally very safe; requires adherence and intact follow-up
Cyanocobalamin IM1 mg IM weekly until corrected, then monthlyAlternative injectable where hydroxocobalamin unavailableAs for hydroxocobalamin
Folic acid (companion, not substitute)5 mg daily for deficiency; 400 micrograms daily preconceptually/antenatallyFolate deficiency; neural-tube-defect preventionNever give folate alone in possible B12 deficiency — it can mask the anaemia while neurological injury progresses

Monitoring and counselling

  • Baseline: record symptoms and a neurological examination, FBC, B12 ± MMA, and the cause assessment.
  • Early response: a reticulocyte rise within days and symptomatic improvement over weeks confirm the diagnosis is behaving; failure suggests wrong diagnosis, mixed deficiency, non-adherence or wrong route.
  • Follow-up: FBC/MCV recovery and neurological review — haematology often corrects before nerves, and neurological recovery may be incomplete if treatment is late.
  • Long-term: adherence, injection schedule or oral supply, recurrent symptoms, cause-specific review.

Counselling: replacement is usually well tolerated; injection-site reactions, headache, nausea and rare hypersensitivity occur; hydroxocobalamin may discolour urine pink-red temporarily. Report worsening weakness, gait change, numbness, breathlessness, chest pain or allergic symptoms. Dietary improvement helps but cannot replace injections where intrinsic factor or ileal absorption is absent.

Clinical scenario

Scenario 1 — Normal Hb, failing nerves

A 62-year-old woman on metformin for six years reports progressive tingling in her feet and unsteadiness in the dark; Hb and MCV are normal. B12 is borderline-low and MMA is elevated — B12 deficiency without anaemia, a classic metformin-associated picture. Treat promptly with IM hydroxocobalamin rather than waiting for macrocytosis, document her neurological deficits at baseline so recovery can be measured, and arrange maintenance therapy. The lesson: the nervous system is the first casualty, not the blood count.

Scenario 2 — The folate trap

A macrocytic patient was given folic acid by a relative; the Hb improved, but his gait has worsened and he now needs support to walk. Urgent assessment confirms severe B12 deficiency with subacute combined degeneration: folate restarted the marrow but did nothing for the cord. Stop folate alone, give IM hydroxocobalamin on the neurological regimen (1 mg alternate days until no further improvement), and counsel that neurological recovery lags haematological recovery and may be incomplete. This is the single most important "never do" in haematinic prescribing.

Key points

References

  • NICE Guideline NG239: Vitamin B12 deficiency in over 16s — diagnosis and management (Library reference.)
  • SlideShare: Vitamin B12, folic acid and megaloblastic anaemias (Library reference.)
  • Davidson's Principles and Practice of Medicine — megaloblastic anaemias (Library reference.)
  • British National Formulary — hydroxocobalamin and cyanocobalamin dosing (Library reference.)

Further reading

For deeper study, compare this lesson with current guidance and standard references from recognised medical and public-health organisations.

For education only. Apply current Uganda Clinical Guidelines, local protocols and specialist advice in clinical practice.

Leave a Comment

Your email address will not be published. Required fields are marked *

Scroll to Top